AMRN

Amarin Corporation plc (AMRN) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Amarin Corporation plc is a pharmaceutical company focused on cardiovascular health, primarily commercializing VASCEPA (icosapent ethyl) in the U.S. and VAZKEPA globally through partnerships. The company operates as a single segment. In June 2025, Amarin executed an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA in 59 European countries, transitioning European commercial operations to Recordati.

Key Financial Metrics (Six Months Ended June 30, 2026)

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 24% year-over-year (YoY) to $87.3 million. This was driven primarily by a $22.2 million decrease in licensing revenue due to the absence of the $25.0 million upfront payment from the Recordati agreement recognized in the prior year. Product revenue decreased 6% to $82.4 million.
• Improved Profitability: Net loss improved significantly to $18.2 million from $29.8 million in the prior year period. Operating loss narrowed to $23.3 million from $32.7 million.
• Cost Reductions: Selling, general, and administrative (SG&A) expenses dropped 42% to $43.3 million, largely due to the Global Restructuring Plan and the transition of European commercial roles to Recordati. Restructuring expenses were $3.4 million compared to $22.8 million in the prior year.
• Gross Margin Compression: Gross margin percentage on product sales decreased to 34% from 55% in the prior year, attributed to a change in customer mix and lower net selling prices in the U.S.
• Market Share Growth: Despite revenue declines, Amarin's share of the U.S. IPE market increased to approximately 49% (from 42% YoY), and branded VASCEPA prescriptions increased 19% YoY.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue competitively managing market leadership in the U.S. and driving expanded access globally through partners. The company anticipates continued support for pricing and reimbursement initiatives in non-U.S. geographies.
• Liquidity: With $314.7 million in cash and investments and no debt, management believes resources are sufficient to fund operations for at least the next 12 months. A $50 million share repurchase program is authorized but has not yet commenced.
• Legal Proceedings:
  • Antitrust Settlement: The company settled six putative antitrust class action lawsuits in April 2026. The settlement payment was recognized in Q1 2026 and settled in Q2 2026.
  • Hikma Litigation: The U.S. Supreme Court reversed a lower court decision in June 2026, ruling that Amarin failed to state a claim for active inducement of patent infringement against Hikma. The case was remanded for further proceedings.
  • Executive Litigation: Ongoing litigation with former CEO Karim Mikhail regarding alleged constructive termination; the company filed a motion to dismiss in February 2026.
• Generic Competition: Multiple generic versions of icosapent ethyl (IPE) are active in the U.S. market for the MARINE indication, impacting pricing and market dynamics.

Investor Verification Checklist

• Recordati Transition Impact: Verify the long-term revenue impact of transitioning European commercial operations to Recordati versus the one-time upfront payment recognized in 2025.
• U.S. Pricing Pressure: Assess the sustainability of the 34% gross margin given the increase in generic competition and the stated "change in customer mix."
• Antitrust Exposure: Monitor the status of the remanded Hikma case and any potential financial exposure from the settled class actions.
• Inventory Levels: Review the $164.1 million inventory balance (43% approved for North America) in the context of declining product revenue to assess obsolescence risk.
• Share Repurchase Activity: Track whether the company initiates the authorized $50 million share repurchase program given the current cash position.